Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection

Trial Profile

A Multi-center, Open-label, Dose-ranging, Phase 1 Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-6150, Administered ID and Followed by Cellectra 2000 Healthy Adults and in Persons Previously Treated for Hepatitis C Virus Infection

Recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Jan 2019

At a glance

  • Drugs DCC 2618 (Primary) ; Sunitinib
  • Indications Gastrointestinal stromal tumours
  • Focus Registrational; Therapeutic Use
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 20 Dec 2018 Status changed from not yet recruiting to recruiting.
    • 14 Sep 2018 Status changed from planning to not yet recruiting.
    • 14 Nov 2017 According to a Deciphera Pharmaceuticals media release, company is planning to initiate the study in second half of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top